CORona Drug InTEractions database

Ivermectin

Synonyms: IVERMECTIN, Ivermectin B1a, Dihydroavermectin B1a, 70288-86-7, 22-23-Dihydroavermectin B1a

Description:

PubChem: Ivermectin is a macrocyclic lactone derived from Streptomyces avermitilis with antiparasitic activity. Ivermectin exerts its anthelmintic effect via activating glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells. Distinct from the channel opening induced by endogenous glutamate transmitter, ivermectin-activated channels open very slowly but essentially irreversibly. As a result, neurons or muscle cells remain at either hyperpolarisation or depolarization state, thereby resulting in paralysis and death of the parasites. Ivermectin does not readily pass the mammal blood-brain barrier to the central nervous system where glutamate-gated chloride channels locate, hence the hosts are relatively resistant to the effects of this agent.

RCSB PDB: 3RHW, IVM

PubChem: 6321424

DrugBank: DB00602

ATC: P02CF01, D11AX22

Related interactions

Target	Drug	Type	Result
Unspecific	Ivermectin
Spike glycoprotein	Ivermectin
3C-like protease	Ivermectin
Angiotensin-converting enzyme 2	Ivermectin
RNA dependent RNA polymerase	Ivermectin
Helicase	Ivermectin
Transmembrane serine 2	Ivermectin
Papain-like proteinases 1/2	Ivermectin
Exoribonuclease	Ivermectin

Related publications

Title	Author	Type
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics	Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Paul O'Neill, Ghaith Aljayyoussi, Shaun Pennington, Stephen A Ward, David J Back, Saye H Khoo, Patrick G Bray, Giancarlo Biagini, Andrew Owen
In Search for Effective and Safe Drugs Against SARS-CoV-2: Part I] Simulated Interactions Between Selected Nutraceuticals, ACE2 Enzyme and S Protein Simple Peptide Sequences	M. Sabry Abdel-Mottaleb, Yousra Abdel-Mottaleb
Old and re-purposed drugs for the treatment of COVID-19	Shio-Shin Jean, Po-Ren Hsueh
Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening	Osmair Vital de Oliveira, Gerd B. Rocha, Andrew S. Paluch, Luciano T. Costa
Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2	Claire Njeri Wamae
Binding Mechanism and Structural Insights into the Identified Protein Target of Covid-19 with In-Vitro Effective Drug Ivermectin	Parth Sarthi Sen Gupta, Satyaranjan Biswal, Saroj Kumar Panda, Abhik Kumar Ray, Malay Kumar Rana
Drug repurposing studies targeting SARS-nCoV2: An ensemble docking approach on drug target 3C-like protease (3CLpro)	Shruti Koulgi, Vinod Jani, Mallikarjunachari Uppuladinne, Uddhavesh Sonavane, A. K. Nath, Hemant Darbari, Rajendra Joshi
Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach	Md. Sorwer Alam Parveza, Md. Adnan Karim, Mahmudul Hasan, Jomana Jaman, Ziaul Karim, Tohura Tahsin, Md. Nazmul Hasan, Mohammad Jakir Hosen
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches	Hourieh Kalhor, Solmaz Sadeghi, Hoda Abolhasani, Reyhaneh Kalhor, Hamzeh Rahimi
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2	Ahmad F. Eweas, Amr A. Alhossary, Ahmed S. Abdel-Moneim4

Target	Target affiliation	Drug	Type	Result
Target	Target affiliation	Drug	Type	Result

Name	Synonyms	Genes	Origin
Name	Synonyms	Genes	Origin

Name	Synonyms	PubChem	DrugBank	RCSB PDB	ATC
Name	Synonyms	PubChem	DrugBank	RCSB PDB	ATC

Title	Authors	DOI	Source	Article type	Date
Title	Authors	DOI	Source	Article type	Date

Title	Status	Phases	Start Date	Prim. Comp. Date	Comp. Date	First Post. Date
Title	Status	Phases	Start Date	Prim. Comp. Date	Comp. Date	First Post. Date

CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID. It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.

The information provided is for research only and we cannot guarantee the correctness of the data.

Please contact dominik.heider@uni-muenster.de for further information.

Programmable access

There is an open API for access programmatically to the database. The API will print a JSON output:

Interactions

https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction

Targets

https://cordite-api.uni-muenster.de/api.php?action=list&table=target

Drugs

https://cordite-api.uni-muenster.de/api.php?action=list&table=drug

Publications

https://cordite-api.uni-muenster.de/api.php?action=list&table=publication

Clinical trials

https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial